Oxaliplatin Accord Healthcare

Oxaliplatin, the active ingredient in Oxaliplatin Accord Healthcare, is a platinum‑based chemotherapy presented as a sterile powder for intravenous infusion use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaliplatin Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oxaliplatin Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oxaliplatin is used primarily for colorectal cancer treatment pathways.

- Colorectal cancer: enhances survival when combined with fluoropyrimidine‑based regimens. - Gastric cancer: used in combination protocols for advanced disease. - Pancreatic cancer: contributes to tumour response in multi‑drug regimens. - Ovarian cancer: employed as part of combination therapy for recurrent disease.

Oxaliplatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Peripheral neuropathy: tingling or numbness, often dose‑related. - Nausea and vomiting: may require anti‑emetic prophylaxis. - Diarrhoea: can be self‑limiting or require supportive care. - Fatigue: generalised tiredness common during treatment cycles. - Thrombocytopenia: reduced platelet count, monitored with blood tests. - Elevated liver enzymes: transient rise in transaminases.

Serious or Rare Side Effects: - Severe peripheral neuropathy: may become irreversible. - Acute allergic reactions: including rash, bronchospasm, or anaphylaxis. - Hematologic toxicity: profound neutropenia or anemia. - Cardiac events: rare cases of arrhythmia or myocardial ischaemia. - Renal impairment: acute kidney injury in susceptible patients. - Severe gastrointestinal toxicity: including colitis or intestinal perforation.

When using Oxaliplatin, clinicians should observe several safety measures.

- Renal function: assess baseline creatinine and adjust if impaired. - Hepatic function: monitor liver enzymes before each cycle. - Neuropathy risk: evaluate pre‑existing neuropathy and adjust dosing. - Hematologic monitoring: perform regular CBC to detect cytopenias. - Pregnancy and lactation: avoid use unless benefits outweigh risks. - Storage: Store below 25°C: keep in the original container, protect from moisture and light.

Oxaliplatin can interact with several concomitant medications, requiring careful management.

Major Interactions (Avoid): - Nephrotoxic agents: concurrent use may exacerbate renal toxicity. - Anticoagulants: increased risk of bleeding due to thrombocytopenia. - Live vaccines: immunosuppression may reduce vaccine efficacy.

Moderate Interactions (Monitor Closely): - Anti‑emetics: certain serotonin‑receptor antagonists may affect drug clearance. - CYP450 inducers: may alter plasma levels of supportive care drugs. - High‑dose folinic acid: can modify toxicity profile.